Literature DB >> 10469407

The natural history of primary herpes simplex type 1 gingivostomatitis in children.

J Amir1, L Harel, Z Smetana, I Varsano.   

Abstract

Herpetic gingivostomatitis is the most common specific clinical manifestation of primary herpes simplex infection in childhood. The aim of the present study was to describe the clinical signs, symptoms, viral shedding, serologic findings, and complications in community-acquired gingivostomatitis. We prospectively followed children with herpes simplex type 1 gingivostomatitis lasting less than 72 hours. Clinical examination and viral culture were repeated every 2 to 3 days as long as symptoms or signs persisted. Thirty-six children (ages 12-77 months) were included in the study. Mean duration of oral lesions was 12.0+/-3.4 days; extraoral lesions (in 26 children), 12.0 +/-3.9 days; fever, 4.4+/-2.4 days; and eating/drinking difficulties, 9.1+/-3.0 and 7.1+/-3.1 days, respectively. In all children, viral cultures of the oral lesions were positive for herpes simplex virus (HSV) type 1; viral shedding persisted for a mean of 7.1+/-2.5 days (range 2-12 days). The main complications were dehydration, with three children hospitalized for intravenous rehydration, and one case of secondary bacteremia. Herpetic gingivostomatitis is a relatively severe manifestation of primary HSV type 1 infection in young children.

Entities:  

Mesh:

Year:  1999        PMID: 10469407     DOI: 10.1046/j.1525-1470.1999.00072.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  7 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 2.  Clinical aspects and antiviral therapy in primary herpetic gingivostomatitis.

Authors:  J Amir
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  The herpes simplex virus type 1 BgKL variant, unlike the BgOL variant, shows a higher association with orolabial infection than with infections at other sites, supporting the variant-dispersion-replacement hypothesis.

Authors:  Shigeru Ozawa; Hiroyuki Eda; Yasuyuki Ishii; Fumihiko Ban; Toshiyuki Funabashi; Seiichiro Hata; Kozaburo Hayashi; Hiroki Iga; Takao Ikushima; Hiroaki Ishiko; Tomoo Itagaki; Rinji Kawana; Shunsaku Kobayashi; Takeo Ogino; Tsuyoshi Sekizawa; Yoshikazu Shimomura; Hiroshi Shiota; Ryoichi Mori; Takashi Nakakita; Yoshio Numazaki; Yoshikatsu Ozaki; Shigeru Yamamoto; Kamesaburo Yoshino; Kazuo Yanagi
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

4.  Acute herpetic gingivostomatitis associated with herpes simplex virus 2: report of a case.

Authors:  Annie Kitty George; Sukumaran Anil
Journal:  J Int Oral Health       Date:  2014-06-26

5.  Repeated social stress enhances the innate immune response to a primary HSV-1 infection in the cornea and trigeminal ganglia of Balb/c mice.

Authors:  P Dong-Newsom; N D Powell; M T Bailey; D A Padgett; J F Sheridan
Journal:  Brain Behav Immun       Date:  2009-10-12       Impact factor: 7.217

Review 6.  Acyclovir for herpetic gingivostomatitis in children.

Authors:  Ran D Goldman
Journal:  Can Fam Physician       Date:  2016-05       Impact factor: 3.275

7.  A double blind, randomised placebo controlled trial of topical 2% viscous lidocaine in improving oral intake in children with painful infectious mouth conditions.

Authors:  Sandy M Hopper; Franz E Babl; Michelle McCarthy; Chasari Tancharoen; Katherine J Lee; Ed Oakley
Journal:  BMC Pediatr       Date:  2011-11-21       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.